Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.
暂无分享,去创建一个
J. Khan | E. Appella | Ying Hu | L. Ozbun | C. Arrowsmith | Chunhua Yan | G. Hager | C. Thiele | G. Giannini | B. Gryder | S. Mazur | T. Voss | Zhihui Liu | V. Veschi | Jian Jin | Anqi Ma | Norris Lam | B. K. Souza
[1] Zhiwei Wang,et al. SCFβ-TRCP promotes cell growth by targeting PR-Set7/Set8 for degradation , 2015, Nature Communications.
[2] P. Raman,et al. A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis. , 2015, Cancer cell.
[3] A. Harris,et al. The role of histone demethylase KDM4B in Myc signaling in neuroblastoma. , 2015, Journal of the National Cancer Institute.
[4] Benjamin G. Bitler,et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.
[5] G. Selivanova,et al. Pharmacological reactivation of p53 as a strategy to treat cancer , 2015, Journal of internal medicine.
[6] Kyle V. Butler,et al. Structure-activity relationship studies of SETD8 inhibitors. , 2014, MedChemComm.
[7] David Shum,et al. Small-Molecule Inhibitors of SETD8 with Cellular Activity , 2014, ACS chemical biology.
[8] Kyle V. Butler,et al. Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8 , 2014, Journal of medicinal chemistry.
[9] R. Boldrini,et al. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors , 2014, Cell Death and Disease.
[10] Eugene S. Kim,et al. Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma. , 2014, Cancer research.
[11] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[12] Giovanni Roti,et al. Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. , 2013, Chemistry & biology.
[13] M. Galka,et al. Dynamic methylation of Numb by Set8 regulates its binding to p53 and apoptosis. , 2013, Molecular cell.
[14] K. Stegmaier,et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.
[15] Steven J. M. Jones,et al. The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.
[16] Giovanni Parmigiani,et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma , 2012, Nature Genetics.
[17] G. Giannini,et al. Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma , 2012, Front. Oncol..
[18] C. Thiele,et al. Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets , 2012, Clinical Cancer Research.
[19] B. Ponder,et al. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression. , 2012, Cancer research.
[20] H. Hakonarson,et al. Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. , 2012, Cancer research.
[21] C. Bountra,et al. Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.
[22] Jinghui Zhang,et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.
[23] D. Zwijnenburg,et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.
[24] Danny Reinberg,et al. PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription. , 2012, Genes & development.
[25] Xiao Han,et al. SET8 promotes epithelial–mesenchymal transition and confers TWIST dual transcriptional activities , 2012, The EMBO journal.
[26] F. Westermann,et al. Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3 , 2011, Molecular Cancer Therapeutics.
[27] Nazneen Rahman,et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene , 2011, Nature.
[28] J. Rice,et al. A new regulator of the cell cycle , 2011, Cell cycle.
[29] M. Kirschner,et al. Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression. , 2010, Genes & development.
[30] Scott L Pomeroy,et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. , 2010, Cancer cell.
[31] J. Maris. Recent advances in neuroblastoma. , 2010, The New England journal of medicine.
[32] M. Wolf,et al. Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication , 2010, BMC Cancer.
[33] Zhe Zhang,et al. Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. , 2010, Cancer research.
[34] F. Speleman,et al. Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis , 2009, Cell Death and Differentiation.
[35] Ruth Ladenstein,et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R. Versteeg,et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. , 2009, Cancer research.
[37] K. Matthay,et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] F. Speleman,et al. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. , 2009, Cancer letters.
[39] M. Malumbres,et al. Genomic stability and tumour suppression by the APC/C cofactor Cdh1 , 2008, Nature Cell Biology.
[40] Or Gozani,et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. , 2007, Molecular cell.
[41] B. Hero,et al. Neuroblastoma , 2007, The Lancet.
[42] Peter A. Jones,et al. The Epigenomics of Cancer , 2007, Cell.
[43] H. Ding,et al. Bmi-1 Regulates the Differentiation and Clonogenic Self-renewal of I-type Neuroblastoma Cells in a Concentration-dependent Manner* , 2006, Journal of Biological Chemistry.
[44] F. Speleman,et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. , 2006, Cancer research.
[45] Y. Suh,et al. HUlip, a human homologue of unc-33-like phosphoprotein of Caenorhabditis elegans; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors , 2005, Journal of Neuro-Oncology.
[46] J. Lunec,et al. The p53 pathway and its inactivation in neuroblastoma. , 2003, Cancer letters.
[47] J. Khan,et al. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. , 2012, Cancer research.